Track the Spectrum Pharmaceuticals INC share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Spectrum Pharmaceuticals INC has published 57 reports. The latest transaction was disclosed on 1 August 2023 (Disposition). Among the most active insiders: McGahan Keith M. Every trade is openly available.
57
Insider Decl.
0
Thresholds
€21,793
1 ops.
Buy Volume
€307,105
36 ops.
Sell Volume
37Σ signal
Buys €21,793€307,105 Sells
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25,000 shares0Common Stock, $0.001 par valueSEC:0001209191-22-048461:0
25 of 57 declarations
About Spectrum Pharmaceuticals INC
Geographically, Spectrum has operated primarily from the United States and serves the U.S. market, with exposure to the country’s healthcare system, payers, and hospital distribution channels. SEC filings also show reliance on third-party manufacturers for certain inputs, active pharmaceutical ingredients, and logistics services, which is important when assessing operational resilience. In short, Spectrum Pharmaceuticals Inc. remains a U.S. biopharmaceutical stock listed on the NASDAQ, with a specialized and higher-risk profile, whose recent history has been defined by portfolio contraction, strategic refocusing, and greater dependence on a limited set of clinical and commercial catalysts.